

# Summary of Relevant Codes\*

\*This guide is offered for informational purposes only and is not intended to provide reimbursement or legal advice. The hospital, pharmacy, or healthcare provider is responsible for determining the appropriate codes, coverage, and payment for individual patients. Sobi, Inc. does not guarantee third-party coverage, or payment, or reimbursement for denied claims.

## Indications and Important Safety Information

### INDICATIONS

Gamifant (emapalumab-lzsg) is an interferon gamma (IFN $\gamma$ )-neutralizing antibody indicated for the treatment of adult and pediatric (newborn and older) patients with:

- Primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy.
- HLH/macrophage activation syndrome (MAS) in known or suspected Still's disease, including systemic Juvenile Idiopathic Arthritis (sJIA), with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS.

### IMPORTANT SAFETY INFORMATION

#### Infections

Gamifant may increase the risk of fatal and serious infections with pathogens including mycobacteria, herpes zoster virus, and histoplasma capsulatum. Do not administer Gamifant in patients with these infections until appropriate treatment has been initiated.

In patients with primary HLH receiving Gamifant in clinical trials, serious infections such as sepsis, pneumonia, bacteremia, disseminated histoplasmosis, necrotizing fasciitis, viral infections, and perforated appendicitis were observed in 32% of patients.

In patients with HLH/MAS in Still's disease receiving Gamifant in clinical trials, serious infections such as pneumonia, cytomegalovirus infection, cytomegalovirus infection reactivation, and sepsis were observed in 13% of patients.

Evaluate patients for tuberculosis risk factors and test for latent infection prior to initiating Gamifant. Administer tuberculosis prophylaxis to patients at risk for tuberculosis or known to have a positive purified protein derivative (PPD) test result.

Consider prophylaxis for herpes zoster, *Pneumocystis jirovecii*, and fungal infection while receiving Gamifant. Employ surveillance testing during treatment with Gamifant.

Closely monitor patients receiving Gamifant for signs or symptoms of infection, promptly initiate a complete diagnostic workup appropriate for an immunocompromised patient, and initiate appropriate antimicrobial therapy.

#### Increased Risk of Infection With Use of Live Vaccines

Do not administer live or live attenuated vaccines to patients receiving Gamifant and for at least 4 weeks after the last dose of Gamifant. The safety of immunization with live vaccines during or following Gamifant therapy has not been studied.

### Infusion-Related Reactions

Infusion-related reactions in patients with primary HLH, including drug eruption, pyrexia, rash, erythema, and hyperhidrosis, were reported with Gamifant treatment in 27% of patients. In one-third of these patients, the infusion-related reaction occurred during the first infusion.

Infusion-related reactions in patients with HLH/MAS in Still's disease, including pyrexia, headache, paresthesia, bone pain, pruritic rash, and peripheral coldness, were reported with Gamifant treatment in 13% of patients. Infusion-related reactions were reported as mild in 8% of patients and as moderate in 5% of patients.

Monitor patients for infusion-related reactions, which can be severe. Interrupt the infusion for infusion reactions and institute appropriate medical management before continuing infusion at a slower rate.

### Adverse Reactions

#### Primary HLH

Serious adverse reactions were reported in 53% of patients. The most common serious adverse reactions ( $\geq 3\%$ ) included infections, gastrointestinal hemorrhage, and multiple organ dysfunction. Fatal adverse reactions occurred in 2 (6%) of patients and included septic shock and gastrointestinal hemorrhage.

The most common adverse reactions were ( $\geq 10\%$ ) for Gamifant included infection (56%), hypertension (41%), infusion-related reactions (27%), pyrexia (24%), hypokalemia (15%), constipation (15%), rash (12%), abdominal pain (12%), CMV infection (12%), diarrhea (12%), lymphocytosis (12%), cough (12%), irritability (12%), tachycardia (12%), and tachypnea (12%).

#### HLH/MAS

Serious adverse reactions were reported in 12 patients (31%), with the most common serious adverse reaction being pneumonia (5%). Fatal adverse reactions occurred in two patients (5%) and included multiple organ dysfunction and circulatory shock.

The most common adverse reactions ( $\geq 10\%$ ) for Gamifant included viral infection (44%), rash (21%), anemia (18%), leukopenia (15%), thrombosis (15%), bacterial infections (13%), headache (13%), hyperglycemia (13%), infusion-related reactions (13%), abdominal pain (10%), hypertension (10%), pyrexia (10%), and thrombocytopenia (10%).

[Click here](#) for full Prescribing Information for Gamifant.

# Preparing for Administration of Gamifant® (emapalumab-lzsg)

## NATIONAL DRUG CODE (NDC) NUMBERS FOR GAMIFANT<sup>1</sup>

NDC Numbers	Description
66658-501-01	One 10 mg/2 mL (5 mg/mL) single-dose vial
66658-505-01	One 50 mg/10 mL (5 mg/mL) single-dose vial
66658-510-01	One 100 mg/20 mL (5 mg/mL) single-dose vial

## ANCILLARY SUPPLIES REQUIRED FOR THE ADMINISTRATION OF GAMIFANT

Item	Specification
Gamma-irradiated or ethylene oxide sterilized, latex-free, polyvinyl chloride (PVC)-free syringes (depending on volume)	50 mL syringe
	20 mL syringe
Non-PVC polyolefin infusion bags (depending on volume)	150 mL infusion bag
	250 mL infusion bag
Non-pyrogenic, low-protein binding filter	0.2 µm filter

For additional information regarding ancillary supplies, including item codes and material availability, contact McKesson at 877-625-2566 or visit [their website](#) to download the latest product guide.

## IMPORTANT SAFETY INFORMATION

### Infections

Gamifant may increase the risk of fatal and serious infections with pathogens including mycobacteria, herpes zoster virus, and histoplasma capsulatum. Do not administer Gamifant in patients with these infections until appropriate treatment has been initiated.

In patients with primary HLH receiving Gamifant in clinical trials, serious infections such as sepsis, pneumonia, bacteremia, disseminated histoplasmosis, necrotizing fasciitis, viral infections, and perforated appendicitis were observed in 32% of patients.

**Please see additional Important Safety Information on page 2. [Click here](#) for full Prescribing Information for Gamifant.**

## Summary of Relevant Codes

### INTERNATIONAL CLASSIFICATION OF DISEASES, TENTH REVISION, CLINICAL MODIFICATION (ICD-10-CM) DIAGNOSIS CODES<sup>2</sup>

ICD-10-CM Codes	Description
D76.1	Hemophagocytic lymphohistiocytosis (HLH)
D76.2	Hemophagocytic syndrome, infection-associated
M06.1	Adult-onset Still's disease
M08.09	Unspecified juvenile rheumatoid arthritis, multiple sites
M08.20	Juvenile rheumatoid arthritis with systemic onset, unspecified site

Social Determinants of Health Codes	Description
Z55	Problems related to education and literacy
Z56	Problems related to employment and unemployment
Z57	Occupational exposure to risk factors
Z59	Problems related to housing and economic circumstances*
Z60	Problems related to social environment
Z62	Problems related to upbringing
Z63	Other problems related to primary support group, including family circumstances
Z64	Problems related to certain psychosocial circumstances
Z65	Problems related to other psychosocial circumstances

\*In 2025, the following codes were changed from nonCC to CC: Z59.10, Z59.11, Z59.12, Z59.19, Z59.811, Z59.812, and Z59.819.<sup>3</sup>

CC=complication or comorbidity.

### IMPORTANT SAFETY INFORMATION (continued)

#### Infections (continued)

In patients with HLH/MAS in Still's disease receiving Gamifant in clinical trials, serious infections such as pneumonia, cytomegalovirus infection, cytomegalovirus infection reactivation, and sepsis were observed in 13% of patients.

Evaluate patients for tuberculosis risk factors and test for latent infection prior to initiating Gamifant. Administer tuberculosis prophylaxis to patients at risk for tuberculosis or known to have a positive purified protein derivative (PPD) test result.

**Please see additional Important Safety Information on page 2. [Click here](#) for full Prescribing Information for Gamifant.**

## Summary of Relevant Codes (continued)

### ENHANCED AMBULATORY PATIENT GROUP (EAPG) CODE<sup>4</sup>

EAPG Code	Description
780	Other hematological diagnoses

### HEALTHCARE COMMON PROCEDURE CODING SYSTEM (HCPCS) CODE FOR PRODUCT<sup>5</sup>

HCPCS Code	Description
J9210	Injection, emapalumab-lzsg, 1 mg

### ADDITIONAL PROCEDURES<sup>5</sup>

HCPCS Code	Description
J1100	Injection, dexamethasone sodium phosphate, 1 mg
G0136	Administration of a standardized, evidence-based social determinants of health risk assessment tool, 5-15 minutes

### DIAGNOSIS-RELATED GROUP (DRG)/ALL PATIENT REFINED (APR)-DRG CODES

DRG Codes <sup>6</sup>	Description
814	Reticuloendothelial & immunity disorders W MCC (with major complications)
815	Reticuloendothelial & immunity disorders W CC (with complications)
816	Reticuloendothelial & immunity disorders W/O CC/MCC (without complications/ major complications)

Medicaid APR-DRG Codes <sup>7</sup>	Description
660-1-660-4	Major hematologic/immunologic diagnosis, except sickle cell crisis & coagulation
663-1-663-4	Other anemias and disorders of blood and blood-forming organs

### IMPORTANT SAFETY INFORMATION (continued)

#### Infections (continued)

Consider prophylaxis for herpes zoster, *Pneumocystis jirovecii*, and fungal infection while receiving Gamifant. Employ surveillance testing during treatment with Gamifant.

Closely monitor patients receiving Gamifant for signs or symptoms of infection, promptly initiate a complete diagnostic workup appropriate for an immunocompromised patient, and initiate appropriate antimicrobial therapy.

**Please see additional Important Safety Information on page 2. [Click here](#) for full Prescribing Information for Gamifant.**

## Summary of Relevant Codes (continued)

### NEW TECHNOLOGY ADD-ON PAYMENT (NTAP) CODE EXAMPLES<sup>8,9</sup>

ICD-10-PCS Codes	Description
<b>XW033MA*</b>	Introduction of emapalumab-lzsg anti-IFN $\gamma$ monoclonal antibody into peripheral vein, percutaneous approach, new technology group 10
<b>XW043MA*</b>	Introduction of emapalumab-lzsg anti-IFN $\gamma$ monoclonal antibody into central vein, percutaneous approach, new technology group 10

\*NTAP application is pending with an expected effective date of October 2026.

### CURRENT PROCEDURAL TERMINOLOGY (CPT<sup>®</sup>) CODE EXAMPLES<sup>10</sup>

Procedure Type	CPT <sup>®</sup> Code	Indications for Testing
Administration	<b>96365</b>	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour

#### Monitoring or Treatment Observation Codes

Platelet counts	<b>85049</b>	Platelet, automated
White blood cell count (WBC) and differential	<b>85004</b> <b>85048</b>	Blood count; automated differential WBC count Leukocyte (WBC), automated
Ferritin	<b>82728</b>	Ferritin
Coagulopathy (D-dimer or fibrinogen)	<b>85610</b>	Monitoring - Prothrombin time
	<b>85730</b>	Monitoring - Partial thromboplastin time (PTT); plasma or whole blood Lab test
	<b>85379</b>	Monitoring - D-dimer Lab test
	<b>85384</b>	Fibrinogen; activity Lab test

ICD-10-PCS=International Classification of Diseases, Tenth Revision, Procedure Coding System; IFN $\gamma$ =interferon gamma.

### IMPORTANT SAFETY INFORMATION (continued)

#### Increased Risk of Infection With Use of Live Vaccines

Do not administer live or live attenuated vaccines to patients receiving Gamifant and for at least 4 weeks after the last dose of Gamifant. The safety of immunization with live vaccines during or following Gamifant therapy has not been studied.

**Please see additional Important Safety Information on page 2. [Click here](#) for full Prescribing Information for Gamifant.**

## Summary of Relevant Codes (continued)

### CPT® CODE EXAMPLES<sup>10</sup> (continued)

#### Monitoring or Treatment Observation Codes (continued)

Splenomegaly	76700	Ultrasound abdomen
	74160	Computerized tomography (CT) scan of the abdomen with contrast
	74150	CT scan of the abdomen without contrast
Fever (WBC)	85025	Complete blood count (CBC) with differential
	85027	CBC without differential
Tuberculosis	86480	Tuberculosis test, cell mediated immunity measurement of gamma interferon antigen response
	86481	Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing T cells in cell suspension
	86580	Skin test for tuberculosis, intradermal
Herpes Zoster	87290	Varicella zoster virus
Adenovirus	87798	Amplified probe technique, each organism
Epstein-Barr virus (EBV)	86664	EBV nuclear antigen
Cytomegalovirus (CMV)	86644	CMV
	86645	CMV, immunoglobulin M
Soluble interleukin 2 (sIL-2)	83520	Quantitative, no otherwise specified Immunoassay

### IMPORTANT SAFETY INFORMATION (continued)

#### Infusion-Related Reactions

Infusion-related reactions in patients with primary HLH, including drug eruption, pyrexia, rash, erythema, and hyperhidrosis, were reported with Gamifant treatment in 27% of patients. In one-third of these patients, the infusion-related reaction occurred during the first infusion.

**Please see additional Important Safety Information on page 2. [Click here](#) for full Prescribing Information for Gamifant.**

## Summary of Relevant Codes (continued)

### CPT® CODE EXAMPLES<sup>10</sup> (continued)

#### Monitoring or Treatment Observation Codes (continued)

Chemokine (C-X-C motif) ligand 9 (CXCL9)	<b>83520</b>	Quantitative, no otherwise specified Immunoassay
Natural killer cells function	<b>88184</b> <b>88185</b>	Flow cytometry analysis: cell surface, cytoplasmic or nuclear markers, and additional markers
Lipid panel test	<b>80061</b>	Lipid panel
Triglyceride	<b>84478</b>	Triglycerides
Cerebrospinal fluid protein	<b>84157</b>	Other source (eg, synovial fluid, cerebrospinal fluid)
Magnetic resonance imaging (MRI)	<b>70551</b> <b>70552</b> <b>70553</b>	Magnetic resonance imaging, brain (including brain stem), with or without contrast material
Lymph node biopsy	<b>38500</b> <b>38505</b>	Biopsy or excision of lymph node(s)

#### Genetic Testing

Genetic testing	<b>81402</b> <b>81403</b> <b>81404</b> <b>81405</b> <b>81406</b> <b>81443</b> <b>81479</b>	HLH genetic analysis with molecular pathology procedure
-----------------	--	---

### IMPORTANT SAFETY INFORMATION (continued)

#### Infusion-Related Reactions (continued)

Infusion-related reactions in patients with HLH/MAS in Still's disease, including pyrexia, headache, paresthesia, bone pain, pruritic rash, and peripheral coldness, were reported with Gamifant treatment in 13% of patients. Infusion-related reactions were reported as mild in 8% of patients and as moderate in 5% of patients.

**Please see additional Important Safety Information on page 2. [Click here](#) for full Prescribing Information for Gamifant.**



# Sample Centers for Medicare & Medicaid Services (CMS) 1450/UB-04 Form

The CMS-1450, also known as the UB-04, form is used to bill for services at institutions such as hospitals and outpatient facilities.<sup>11</sup> However, providers should check with commercial and government payers to ensure the proper claim form is used.

**Fields 42 and 43:** Include appropriate revenue codes and descriptions in ascending order. When including Gamifant® (emapalumab-lzsg), please indicate NDC number.

**Field 44:** Indicate the appropriate HCPCS and/or CPT® codes.

**Field 46:** Indicate the appropriate HCPCS and/or CPT® codes.

**Field 56:** Indicate appropriate National Provider Identifier (NPI) number.

**Field 67:** Enter the appropriate primary ICD-10-CM diagnosis code.

**Field 69:** Enter the admitting diagnosis.

## IMPORTANT SAFETY INFORMATION (continued)

### Infusion-Related Reactions (continued)

Monitor patients for infusion-related reactions, which can be severe. Interrupt the infusion for infusion reactions and institute appropriate medical management before continuing infusion at a slower rate.

**Please see additional Important Safety Information on page 2. [Click here](#) for full Prescribing Information for Gamifant.**

## REFERENCES:

1. Gamifant (emapalumab-lzsg) prescribing information. Stockholm, Sweden: Sobi, Inc. 2025.
2. ICD-10-CM tabular list of diseases and injuries. Centers for Medicare & Medicaid Services. Published April 2022. Accessed May 6, 2025. [https://ftp.cdc.gov/pub/health\\_statistics/nchs/Publications/ICD10CM/2022/icd10cm-tabular-2022-April-1.pdf](https://ftp.cdc.gov/pub/health_statistics/nchs/Publications/ICD10CM/2022/icd10cm-tabular-2022-April-1.pdf)
3. Centers for Medicare & Medicaid Services. Department of Health and Human Services. Medicare and Medicaid programs and the Children's Health Insurance Program; hospital inpatient prospective payment systems for acute care hospitals and the long-term care hospital prospective payment system and policy changes and fiscal year 2025 rates; quality programs requirements; and other policy changes. *Federal Register*. 2024;89(167):68986-70046.
4. 3M Health Information Systems. EAPG listing: effective October 1, 2018. Published August 23, 2018. Accessed May 7, 2025. [https://dhcf.dc.gov/sites/default/files/dc/sites/dhcf/page\\_content/attachments/DC%20EAPG%20Relative%20Weights%20Eff%2010-1-18%20DCO18023.pdf](https://dhcf.dc.gov/sites/default/files/dc/sites/dhcf/page_content/attachments/DC%20EAPG%20Relative%20Weights%20Eff%2010-1-18%20DCO18023.pdf)
5. Alpha-Numeric HCPCS 2025. Centers for Medicare & Medicaid Services website. Updated May 6, 2025. Accessed May 7, 2025. <https://www.cms.gov/files/zip/july-2025-alpha-numeric-hcpcs-file.zip>
6. Diseases & disorders of blood, blood-forming organs, immunologic disorders DRG Code Range 799-816. Codify website. Accessed May 7, 2025. <https://www.aapc.com/codes/drg-codes-range/17>
7. Final APR-DRG Weights Effective July 1, 2018 (v34). New York State Department of Health website. Updated January 2, 2019. Accessed May 7, 2025. [https://www.health.ny.gov/facilities/hospital/reimbursement/apr-drg/weights/2018-07-01\\_final\\_weights.htm](https://www.health.ny.gov/facilities/hospital/reimbursement/apr-drg/weights/2018-07-01_final_weights.htm)
8. XW033MA. Codify website. Accessed May 15, 2025. <https://www.aapc.com/codes/pcs-code/XW033MA>
9. XW043MA. Codify website. Accessed May 15, 2025. <https://www.aapc.com/codes/pcs-code/XW043MA>
10. American Medical Association. *CPT® 2024 Professional Edition*. Chicago, IL: American Medical Association; 2024.
11. What is the difference between HCFA-1500 (CMS 1500) and UB-04 (CMS 1450)? UB-04 Software website. Accessed May 7, 2025. <https://ub04software.com/about/news-press/what-is-the-difference-between-hcfa-1500-cms-1500-and-ub-04-cms-1450>

IMPORTANT INFORMATION: Any coding, coverage, payment, or other information contained herein is gathered from various resources, general in nature, and subject to change without notice. Third-party payment for medical products and services is affected by numerous factors. It is always the provider's responsibility to determine the appropriate healthcare setting and to submit true and correct claims conforming to the requirements of the relevant payer for those products and services rendered. Hospitals and pharmacies (or any other provider submitting a claim) should contact third-party payers for specific information on their coding, coverage, and payment policies. Information and materials provided by Gamifant Cares are to assist providers, but the responsibility to determine coverage, reimbursement, and appropriate coding for a particular patient and/or procedure remains at all times with the provider and information provided by Gamifant Cares or Sobi, Inc. should in no way be considered a guarantee of coverage or reimbursement for any product or service.

[Click here](#) for full Prescribing Information for Gamifant.

For statutory pricing disclosures, please [click here](#) for more information.